我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300357 我武生物

已收盘 09-30 15:00:00

{"stockData":{"symbol":"300357","market":"SZ","secType":"STK","nameCN":"我武生物","latestPrice":20.33,"timestamp":1790751822000,"preClose":19.82,"halted":0,"volume":10278491,"delay":0,"changeRate":0.0257,"floatShares":484999999,"shares":524000000,"eps":0.7972,"marketStatus":"已收盘","change":0.51,"latestTime":"09-30 15:00:00","open":19.84,"high":20.66,"low":19.8,"amount":210000000,"amplitude":0.0434,"askPrice":20.33,"askSize":6,"bidPrice":20.32,"bidSize":335,"shortable":0,"etf":0,"ttmEps":0.7972,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"adjPreClose":19.82,"symbolType":"stock","openAndCloseTimeList":[[1790731800000,1790739000000],[1790744400000,1790751600000]],"highLimit":21.8,"lowLimit":17.84,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":523584000,"isCdr":false,"pbRate":3.77,"roa":"--","peRate":25.501756,"roe":"7.87%","epsLYR":0.7276,"committee":0.535117,"marketValue":10644000000,"turnoverRate":0.0212,"status":0,"floatMarketCap":9868000000},"requestUrl":"/m/hq/s/300357","defaultTab":"news","newsList":[{"id":"2669155284","title":"我武生物：粉尘螨滴剂新生产线待GMP检查后投产","url":"https://stock-news.laohu8.com/highlight/detail?id=2669155284","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669155284?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:57","pubTimestamp":1789977434,"startTime":"0","endTime":"0","summary":"我武生物回复：投资者您好，2026年7月，公司产品“粉尘螨滴剂”获得国家药品监督管理局核准签发的《药品补充申请批准通知书》，该品种变更生产线和扩大生产规模的补充申请获得批准，待新生产线通过GMP符合性检查后，“粉尘螨滴剂”新生产线即可正式投产。关于粉尘螨滴剂产能，公司会结合市场情况与患者需求合理规划。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100016847.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300357","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667605069","title":"我武生物：您提及的项目并非由上市公司投资","url":"https://stock-news.laohu8.com/highlight/detail?id=2667605069","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667605069?lang=zh_cn&edition=full","pubTime":"2026-09-16 16:09","pubTimestamp":1789546149,"startTime":"0","endTime":"0","summary":"证券之星消息，我武生物09月16日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问：1、浙江新秋合伙企业设立的目的与具体投资方向是什么？我武咨询对新秋合伙5.99亿出资，资金来源是否为本次3500万股股权质押的融资款？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600023509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667680193","title":"股市必读：我武生物（300357）9月11日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2667680193","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667680193?lang=zh_cn&edition=full","pubTime":"2026-09-14 02:06","pubTimestamp":1789322775,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，我武生物报收于18.98元，下跌2.32%，换手率1.98%，成交量9.6万手，成交额1.82亿元。董秘最新回复投资者： 2026年8月3日，胡赓雄注册成立“绍兴黑铁企业管理有限公司”，注册资本200万。9月7日，我武咨询质押3500万股我武生物。9月8日，陈燕霓和胡赓熙公布离婚，胡赓熙辞去所有职务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400000839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666547086","title":"我武生物：我武咨询质押股份数量35,000,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666547086","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666547086?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:51","pubTimestamp":1789116687,"startTime":"0","endTime":"0","summary":"8月25日，浙江我武管理咨询有限公司与绍兴黑铁合伙成立“浙江新秋企业管理咨询合伙企业”，注册资本金60000万元，我武咨询出资59900万元，绍兴黑铁出资100万元并成为执行事务合伙人。9月7日，我武咨询质押3500万股我武生物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100036337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666260511","title":"【机构调研记录】汇添富基金调研我武生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2666260511","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666260511?lang=zh_cn&edition=full","pubTime":"2026-09-11 08:05","pubTimestamp":1789085114,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及9月10日披露的机构调研信息，汇添富基金近期对1家上市公司进行了调研，相关名单如下：1）我武生物 调研纪要：胡赓熙先生离任不会影响公司正常运作，管理层交接平稳，有信心维持长期良好运营。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100013966.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666511222","title":"【机构调研记录】嘉实基金调研茂莱光学、我武生物等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2666511222","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666511222?lang=zh_cn&edition=full","pubTime":"2026-09-11 08:05","pubTimestamp":1789085105,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及9月10日披露的机构调研信息，嘉实基金近期对3家上市公司进行了调研，相关名单如下：1）茂莱光学 调研纪要：公司于2026年4月设立全资子公司南京茂莱光互连科技有限公司，聚焦光通信领域，推进激光通信、卫星通信及近地卫星通信业务布局，截至2026年6月底尚处早期开发阶段。陈燕霓女士继续在董事会参与决策。不排除未来开展股权激励，将依法披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100013947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0225","688502","300357","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666212511","title":"【私募调研记录】明汯投资调研奥比中光、我武生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2666212511","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666212511?lang=zh_cn&edition=full","pubTime":"2026-09-11 08:04","pubTimestamp":1789085085,"startTime":"0","endTime":"0","summary":"根据市场公开信息及9月10日披露的机构调研信息，知名私募明汯投资近期对2家上市公司进行了调研，相关名单如下：1）奥比中光 调研纪要：公司认为机器人商业化核心在于应用场景需求清晰、技术成熟与安全可控，看好服务、移动、工业及具身智能机器人发展。明汯投资业务涵盖市场分析、策略开发、资产配置、风险管理及系统开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026091100013894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666258587","title":"A股再现天价离婚！我武生物创始人出局，前妻挑大梁","url":"https://stock-news.laohu8.com/highlight/detail?id=2666258587","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666258587?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:09","pubTimestamp":1788952140,"startTime":"0","endTime":"0","summary":"此次离婚财产分割，主要涉及胡赓熙与陈燕霓合计控制的我武生物47.20%股份。离婚并辞职的创始人胡赓熙是公司的灵魂人物。对这次变动，我武生物强调，本次权益变动系离婚财产分割所致，属于非交易变动，其他董事、高管均未发生变化。对于盛行一时的离婚减持，目前A股也有诸多约束。6月5日，我武生物公告与IPO前股东上海利合股权投资合伙企业的二审终审判决出炉：驳回上诉，维持原判。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-09-09/doc-inirfqcu8561728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK1147","159982","BK0028","02827","02846","300357","399300","03130","03188","07233","83188","83130","82846"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666884045","title":"我武生物：公司经营管理层保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=2666884045","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666884045?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:27","pubTimestamp":1788938830,"startTime":"0","endTime":"0","summary":"投资者提问：请问1.胡赓熙辞任后，公司研发管线、销售策略是否出现重大调整；2.女儿胡沐霜的接班进度与管理权限，是否能平稳完成代际交接；3.三季报及后续业绩是否能维持增长我武生物回复：投资者您好，公司经营管理层保持稳定，研发管线、营销策略等均不会有重大调整，公司生产经营一切正常。胡赓熙先生的离任不会影响公司正常运作，公司将按照法定程序尽快完成相关人员的补选工作，确保平稳过渡。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900020679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666304845","title":"A股异动丨我武生物大跌8.5% 创始人辞职+实控人变更 市场担忧战略连续性","url":"https://stock-news.laohu8.com/highlight/detail?id=2666304845","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666304845?lang=zh_cn&edition=full","pubTime":"2026-09-09 11:48","pubTimestamp":1788925724,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["399300","159982","300357","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665376013","title":"我武生物最新公告：董事长胡赓熙辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2665376013","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665376013?lang=zh_cn&edition=full","pubTime":"2026-09-08 22:49","pubTimestamp":1788878961,"startTime":"0","endTime":"0","summary":"我武生物公告称，公司董事长胡赓熙因个人原因辞去董事长、董事等职务，不再担任公司任何职务。辞任自公司收到其辞职报告时生效，不影响公司正常运作。公司已安排董事YANNICHEN代行董事长职责，并将尽快完成补选。截至公告日，胡赓熙直接持有公司8.35%股份。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800037913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322299","title":"我武生物：实控人变更为YANNI CHEN","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322299","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665322299?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:10","pubTimestamp":1788865844,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["300357","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322207","title":"我武生物最新公告：实控人变更为YANNICHEN","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322207","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665322207?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:10","pubTimestamp":1788865819,"startTime":"0","endTime":"0","summary":"我武生物公告称，因胡赓熙与YANNI CHEN解除婚姻关系并进行财产分割，公司实控人由二人共同控制变更为YANNI CHEN一人。控股股东仍为我武咨询，持股38.86%。胡赓熙单独持股8.35%，辞去公司董事长等职务，不再担任公司任何职务。本次变动不会对公司生产经营产生重大影响。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800032011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664583458","title":"西南证券：给予我武生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664583458","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664583458?lang=zh_cn&edition=full","pubTime":"2026-09-01 18:08","pubTimestamp":1788257308,"startTime":"0","endTime":"0","summary":"西南证券股份有限公司杜向阳近期对我武生物进行研究并发布了研究报告《2026半年报点评：黄花蒿滴剂延续高增，收入稳健增长》，给予我武生物买入评级。公司核心产品收入稳健增长，黄花蒿滴剂贡献新的收入增量，研发管线有序推进，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。)本文数据来源于西南证券股份有限公司，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100032381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","600369"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663028138","title":"【机构调研记录】浙商基金调研我武生物、伟思医疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2663028138","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663028138?lang=zh_cn&edition=full","pubTime":"2026-08-31 08:03","pubTimestamp":1788134630,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月28日披露的机构调研信息，浙商基金近期对2家上市公司进行了调研，相关名单如下：1）我武生物 调研纪要：公司上半年营收和利润受到增值税政策调整影响，粉尘螨滴剂等产品税率由3%升至13%，叠加去年同期高基数，增速有所放缓。浙商基金成立于2010年，截至目前，资产管理规模254.44亿元，排名115/212；资产管理规模197.56亿元，排名110/212；管理公募基金数76只，排名83/212；旗下公募基金经理13人，排名97/212。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100002156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688580","BK0028","BK0251","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662706040","title":"开源证券：给予我武生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662706040","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662706040?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:54","pubTimestamp":1787918084,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,阮帅近期对我武生物进行研究并发布了研究报告《公司信息更新报告：2026上半年稳健增长，黄花蒿花粉滴剂快速放量》，给予我武生物买入评级。最新盈利预测明细如下：该股最近90天内共有2家机构给出评级，买入评级1家，增持评级1家。)本文数据来源于开源证券股份有限公司，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800048321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662066233","title":"我武生物(300357)6月30日股东户数3.53万户，较上期减少0.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662066233","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662066233?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:52","pubTimestamp":1787910755,"startTime":"0","endTime":"0","summary":"证券之星消息，近日我武生物披露，截至2026年6月30日公司股东户数为3.53万户，较3月31日减少309.0户，减幅为0.87%。在生物制品行业个股中，我武生物股东户数低于行业平均水平，截至6月30日，生物制品行业平均股东户数为3.54万户。从股价来看，2026年3月31日至2026年6月30日，我武生物区间跌幅为9.19%，在此期间股东户数减少309.0户，减幅为0.87%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800041480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662087204","title":"图解我武生物中报：第二季度单季净利润同比下降8.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662087204","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662087204?lang=zh_cn&edition=full","pubTime":"2026-08-28 02:44","pubTimestamp":1787856250,"startTime":"0","endTime":"0","summary":"证券之星消息，我武生物2026年中报显示，上半年度公司主营收入5.14亿元，同比上升6.18%；归母净利润2.13亿元，同比上升20.59%；扣非净利润1.83亿元，同比上升6.05%；其中2026年第二季度，公司单季度主营收入2.61亿元，同比上升2.17%；单季度归母净利润9421.96万元，同比下降8.23%；单季度扣非净利润9368.81万元，同比下降5.34%；负债率7.71%，投资收益2903.26万元，财务费用-872.28万元，毛利率95.29%。财报数据概要请见下图:本文数据来源于我武生物2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800006041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662787315","title":"我武生物：将持续加大“黄花蒿花粉变应原舌下滴剂”（商品名","url":"https://stock-news.laohu8.com/highlight/detail?id=2662787315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662787315?lang=zh_cn&edition=full","pubTime":"2026-08-25 16:48","pubTimestamp":1787647693,"startTime":"0","endTime":"0","summary":"公司将持续加大“黄花蒿花粉变应原舌下滴剂”的推广力度。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。过敏原特异性免疫治疗 ，即脱敏治疗，是世界卫生组织推荐的唯一可能影响过敏性疾病自然进程的“对因治疗”方法。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500034104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661261318","title":"我武生物最新公告：获得猫毛膜剂药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2661261318","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661261318?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:50","pubTimestamp":1787305818,"startTime":"0","endTime":"0","summary":"我武生物公告称，公司从国家药品监督管理局政务服务门户网站下载获得《药物临床试验批准通知书》，由公司提交的“猫毛膜剂”药物临床试验申请获得批准。截至公告披露日，尚未有其他企业取得该品种的《药品注册证书》。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100033011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790798962523,"stockEarnings":[{"period":"1week","weight":-0.0029},{"period":"1month","weight":-0.0912},{"period":"3month","weight":-0.1492},{"period":"6month","weight":-0.1985},{"period":"1year","weight":-0.2967},{"period":"ytd","weight":-0.2758}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江我武生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"35260人(较上一季度减少0.87%)","perCapita":"13766股","listingDate":"2014-01-21","address":"浙江省湖州市德清县武康镇志远北路636号","registeredCapital":"52358万元","survey":"　　浙江我武生物科技股份有限公司的主营业务是过敏性疾病诊断及治疗产品的研发、生产和销售。公司的主要产品是粉尘螨滴剂、黄花蒿花粉变应原舌下滴剂、粉尘螨皮肤点刺诊断试剂盒等系列点刺液产品。","listedPrice":20.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"我武生物,300357,我武生物股票,我武生物股票老虎,我武生物股票老虎国际,我武生物行情,我武生物股票行情,我武生物股价,我武生物股市,我武生物股票价格,我武生物股票交易,我武生物股票购买,我武生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}